Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3

[1]  T. Veikkola,et al.  Adenoviral VEGF‐C overexpression induces blood vessel enlargement, tortuosity, and leakiness but no sprouting angiogenesis in the skin or mucous membranes , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  P. Carmeliet,et al.  Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. , 2004, Biochemical and biophysical research communications.

[3]  K. Opeskin,et al.  Tumor-induced activation of lymphatic endothelial cells via vascular endothelial growth factor receptor-2 is critical for prostate cancer lymphatic metastasis. , 2006, Cancer research.

[4]  K. Alitalo,et al.  Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. , 2008, Cancer research.

[5]  Lena Claesson-Welsh,et al.  Ligand-induced Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) Heterodimerization with VEGFR-2 in Primary Lymphatic Endothelial Cells Regulates Tyrosine Phosphorylation Sites* , 2003, Journal of Biological Chemistry.

[6]  Tatiana V. Petrova,et al.  Lymphangiogenesis in development and human disease , 2005, Nature.

[7]  Seppo Ylä-Herttuala,et al.  Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3 , 2001, Nature Medicine.

[8]  D. Hicklin,et al.  Cooperative and redundant roles of VEGFR‐2 and VEGFR‐3 signaling in adult lymphangiogenesis , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  M. Detmar,et al.  Pathways Targeting Tumor Lymphangiogenesis , 2006, Clinical Cancer Research.

[10]  W. Jiang,et al.  Lymphangiogenesis and cancer metastasis. , 2011, Frontiers in bioscience.

[11]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[12]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[13]  小寺 康夫.  Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3 , 2012 .

[14]  K. Alitalo,et al.  Lymphangiogenesis and cancer metastasis. , 2006 .

[15]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[16]  Bernadette M. M. Zwaans,et al.  Potential therapeutic strategies for lymphatic metastasis. , 2007, Microvascular research.

[17]  K. Alitalo,et al.  Metastasis: Lymphangiogenesis and cancer metastasis , 2002, Nature Reviews Cancer.

[18]  D. Kerjaschki,et al.  Isolation and Characterization of Dermal Lymphatic and Blood Endothelial Cells Reveal Stable and Functionally Specialized Cell Lineages , 2001, The Journal of experimental medicine.

[19]  K. Alitalo,et al.  The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. , 2008, Cancer research.

[20]  M. Skobe,et al.  Molecular characterization of lymphatic endothelial cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Thomas Hawighorst,et al.  Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis , 2001, Nature Medicine.

[22]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[23]  J. Wood,et al.  Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis , 2009, Molecular Cancer Therapeutics.

[24]  G. Demetri,et al.  Molecular basis for sunitinib efficacy and future clinical development , 2007, Nature Reviews Drug Discovery.

[25]  A. Ryan,et al.  Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines , 2009, Molecular Cancer Therapeutics.

[26]  S. Stacker,et al.  Focus on lymphangiogenesis in tumor metastasis. , 2005, Cancer cell.

[27]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[28]  K. Alitalo,et al.  Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. , 1998, Science.

[29]  K. Alitalo,et al.  Lymphangiogenesis: Molecular Mechanisms and Future Promise , 2010, Cell.

[30]  K. Alitalo,et al.  Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. , 2002, Journal of the National Cancer Institute.

[31]  D. Jenkins,et al.  Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice , 2005, Breast Cancer Research.

[32]  Dominique,et al.  Combining Agents that Target the Tumor Microenvironment Improves the Efficacy of Anticancer Therapy , 2008, Clinical Cancer Research.

[33]  S. Baruchel,et al.  In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. , 2009, Neoplasia.

[34]  Y. Funahashi,et al.  Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase , 2008, Clinical Cancer Research.

[35]  M. Skobe,et al.  Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. , 2006, Cancer research.

[36]  T. Itakura,et al.  Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III , 2008, Cancer science.

[37]  K. Alitalo,et al.  Molecular regulation of angiogenesis and lymphangiogenesis , 2007, Nature Reviews Molecular Cell Biology.